Germline testing for prostate cancer is becoming central to cancer care. Multiple genes predict risk for prostate cancer to varying degrees, and several are now crucial to candidacy for precision therapies for men with metastatic prostate cancer. Across the stage and risk spectrum, germline testing is relevant for informing hereditary cancer risks for men and their families. Given this rising volume of men meeting criteria for genetic testing, there is a need to address delivery of germline testing and genetic counseling. This presentation will provide a brief overview of genetic contribution to prostate cancer risk and precision treatment, principles of genetic counseling, and guidance on delivery of germline prostate cancer testing from the 2019 Philadelphia Prostate Cancer Consensus Conference.